Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2013 Financials
Date:11/12/2013

, compared to $23.8 million in the comparable period of 2012.  This also reflects increased spending in 2013 for BDSI's Phase 3 clinical trials.  

Recently BDSI has made important personnel additions in preparation for commercialization of BUNAVAIL in 2014.  In July, BDSI announced the hiring of Adrian Hepner, MD, as Vice President of Clinical Research and Regulatory Affairs.  Dr. Hepner joined BDSI with over twenty years of experience in U.S. and international clinical research.  More recently, in October, BDSI strengthened its senior management team with the appointment of Ernest De Paolantonio as Chief Financial Officer.  Mr. De Paolantonio is an experienced industry veteran of over 35 years and has been involved in numerous product launches at GlaxoSmithKline, Watson, Columbia Laboratories, and most recently, CorePharma.     

"We are pleased with all of our third quarter accomplishments and particularly excited that the NDA for BUNAVAIL has been accepted for review, and we look forward to working with the FDA toward approval next year," said Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  "The opioid dependence market continues to grow, and we believe that caregivers and patients are eager to see alternatives to the currently available therapies.  We are actively exploring all aspects of our commercial plans for BUNAVAIL and expect to have additional details early next year." 

"We also look forward beginning in early 2014 to the results from our two Phase 3 pivotal trials from the BEMA Buprenorphine program for chronic pain," continued Dr. Sirgo.  "Importantly, the completion of each of these trials is associated with a guaranteed milestone payment from our commercial partner Endo.  The recent interim analyses on these two trials enhance our confidence
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference
2. Endo and BioDelivery Sciences Provide Update on BEMA Buprenorphine Phase III Development Program
3. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials
4. BioDelivery Sciences Announces Submission of NDA for BUNAVAIL
5. BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
6. BioDelivery Sciences to Present at the William Blair 33rd Annual Growth Stock Conference
7. BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference
8. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
9. BioDelivery Sciences Appoints Thomas W. DAlonzo to Board of Directors
10. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
11. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... LAS VEGAS , March 26, 2015 Zimmer ... of a new mobile app designed to serve as a ... Hyaluronate product. For those experiencing knee ... valuable information about the causes of knee pain and helps ... Hyaluronate as a safe and simple non-surgical treatment option. For ...
(Date:3/26/2015)... Californie, 26 mars 2015 Finesse Solutions ... conçu pour les innovateurs, visionnaires et cadres de ... conférence d,une durée de deux jours proposée exclusivement ... dans le centre ville de San ... 2015. Il s,agira d,un forum destiné aux leaders ...
(Date:3/26/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx") today ... from the Israeli patent office with claims for administering ... damage caused by an increase in blood flow, as ... after a blockage causing a heart attack or in ... can be caused to the heart attack or stroke ...
Breaking Medicine Technology:Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate 2Finesse Solutions annonce l'événement Cellworld 2015 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3
... NESHER, Israel, April 21 NanoVibronix, a ... surface ultrasound waves,announced that its novel device ... claims of wound healing. PainShield is the ... waves for therapeutic,treatment of wounds. The innovative ...
... - Preclinical Studies Highlight the Ability of PS-Targeting ... Tumors by Changing the Tumor Microenvironment and Mobilizing ... Studies Confirm Peregrine,s PS-Targeting Antibodies Stimulate Dendritic Cell ... of Macrophages to Tumors -DENVER and TUSTIN, Calif., ...
Cached Medicine Technology:NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device 2Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 2Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 3Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 4Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 5Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 6Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 7
(Date:3/26/2015)... Md. (PRWEB) March 26, 2015 ... than $11.3 billion in 2014, according to an ... , The Annapolis-based healthcare real estate (HRE) data ... board members and two new Gold-Level Partners: Harrison ... Investment Services. , MOB transactions still going strong, ...
(Date:3/26/2015)... 2015 Pacific Medical LLC, the leader ... be featured on Innovations with Ed Begley Jr, which ... The episode will repeat on local cable channels ... Pacific Medical home page at: http://www.pacificmedicalsupply.com . ... is reassuring to trust the integrity of the medical ...
(Date:3/26/2015)... On March 5, 2015, Portland Trail ... for the season with a torn Achilles tendon in ... Blazers were competing against Dallas, and was confirmed via ... Silva, M.D., who has treated many professional athletes, voiced ... could be prevented. , "Part of the problem ...
(Date:3/26/2015)... In the key developed markets, the hypertension market value ... to decrease through 2020 at a negative CAGR (0.9%) to ... to 2017 at a 2.6% CAGR and a decline thereafter. ... surging penetration of fixed-dose combination drugs like Azor, Amturnide, Exforge ... and Tekamlo), a hike in the prevalence population to 190 ...
(Date:3/26/2015)... March 26, 2015 In preparation for ... Fitness Revolution, founded by Samir Becic, has issued ... own personal health and fitness, as well as their ... The list includes Sen. Ted Cruz, who has officially ... as all other politicians who have shown interest in ...
Breaking Medicine News(10 mins):Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 2Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 3Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 4Health News:Pacific Medical Featured on the Discovery Channel 2Health News:Pacific Medical Featured on the Discovery Channel 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3
... they are admitted to hospital may be one way to ... today’s BMJ. ,Recent data published by the Health ... 7,000 inpatients have MRSA infections and more than 50,000 inpatients ... of C difficile rose by 5.5% in 2006, whereas MRSA ...
... by blocking the lifesaving effects of aspirin//, a new study ... monstrous," Michael Farkouh, director of clinical trials at Mount Sinai ... ,“Ibuprofen is relatively safe except when we give it ... Farkouh says. "But when given with aspirin, we do we ...
... couple of months, 100,000 doses of the country's first vaccine ... developed it has found no takers //and the expiry date ... year that the High Security Animal Disease Laboratory (HSADL) here ... about 100,000 doses of the vaccine, each costing just 27 ...
... mammograms are more likely to interpret a benign growth ... and experience," and CAD systems do not help detect ... systems use complex algorithms to identify "suspicious" areas of ... which cost $50,000 to $175,000, were approved by FDA ...
... The Food and Drug Administration (FDA) today warned consumers ... Chews and Dog Chews manufactured// and distributed by T.W. ... have the potential to be contaminated with Salmonella, which ... if there is cross contamination, in people, especially children, ...
... Foundation on Wednesday announced that it will spend $500 ... address childhood obesity//, particularly targeting minority children, who are ... ,Nearly 25 million children under age 18 are considered ... medical expenses, according to the foundation. ,The ...
Cached Medicine News:Health News:Ibuprofen Risky for Heart Patients? 2Health News:100,000 Bird Flu Vaccine Doses to Be Destroyed 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: